Plus Therapeutics Inc [NASDAQ: PSTV] stock went on a downward path that fall over -34.38% on Wednesday, amounting to a one-week price decrease of less than -38.64%.
Over the last 12 months, PSTV stock dropped by -89.87%. The one-year Plus Therapeutics Inc stock forecast points to a potential upside of 97.95. The average equity rating for PSTV stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $6.63 million, with 32.72 million shares outstanding and 29.81 million shares in the current float. Compared to the average trading volume of 12.82M shares, PSTV stock reached a trading volume of 23264398 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Plus Therapeutics Inc [PSTV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PSTV shares is $9.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PSTV stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
D. Boral Capital have made an estimate for Plus Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 17, 2025. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on January 25, 2021, representing the official price target for Plus Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while Maxim Group analysts kept a Buy rating on PSTV stock.
The Average True Range (ATR) for Plus Therapeutics Inc is set at 0.08, with the Price to Sales ratio for PSTV stock in the period of the last 12 months amounting to 1.27.
PSTV Stock Performance Analysis:
Plus Therapeutics Inc [PSTV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -38.64. With this latest performance, PSTV shares dropped by -39.55% in over the last four-week period, additionally sinking by -84.06% over the last 6 months – not to mention a drop of -89.87% in the past year of trading.
Insight into Plus Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Plus Therapeutics Inc [PSTV] shares currently have an operating margin of -286.82% and a Gross Margin at 83.73%. Plus Therapeutics Inc’s Net Margin is presently recorded at -520.90%.
Return on Equity for this stock declined to -306.82%, with Return on Assets sitting at -306.82%.
PSTV Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PSTV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Plus Therapeutics Inc go to 49.89%.
Plus Therapeutics Inc [PSTV] Institutonal Ownership Details
The top three institutional holders of PSTV stocks are: AIGH CAPITAL MANAGEMENT LLC with ownership of 0.57 million shares, which is approximately 8.7478%. GEODE CAPITAL MANAGEMENT, LLC, holding 46648.0 shares of the stock with an approximate value of $$68572.0 in PSTV stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $$47835.0 in PSTV stock with ownership which is approximately 0.5006%.
